American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium

Even men who test negative for mutations in the BRCA1/2 DNA repair genes may have increased risk for prostate cancer progression when they have certain family history.

During the COVID-19 pandemic, neoadjuvant ADT has been used as a way to delay initiation of daily radiation therapy, but it may not be appropriate for all men.